It all depends on where you got in. Is it going back to $6 or to $30?
LA JOLLA, Calif., Nov. 15, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that positive new preclinical data was presented on RG-012 for the treatment of renal dysfunction in Alport syndrome patients at the American Society of Nephrology's (ASN) Kidney Week 2014 meeting being held November 11-16, 2014 in Philadelphia, PA. Alport syndrome is a life-threatening, genetic kidney disease with no approved therapy, and currently, ACE (angiotensin-converting enzyme) inhibitors are emerging as standard of care to treat proteinuria, an indicator of chronic kidney disease (CKD) in these patients. Studies have shown that miR-21 plays a role in the progression of Alport syndrome and is up-regulated in mouse disease models, other renal fibrosis models and human CKD patients. These findings, and the new preclinical data presented at the ASN meeting, provide additional evidence that RG-012 may provide therapeutic benefit in the treatment of Alport syndrome.
In an oral presentation titled "Anti-miR-21 as a Potential Novel Therapy for Both Early and Late Stages of Alport Syndrome", Regulus' strategic alliance partner, Genzyme, a Sanofi company, presented new data demonstrating that treatment with RG-012 in a mouse model of disease improves renal function, protects against kidney damage and extents the lifespan of the mice when treatment begins at both early and late stages of the disease by reversing multiple dysregulated pathways. Further, combination studies were performed with RG-012 and ramipril, Sanofi's ACE inhibitor, a kidney protectant, to assess the therapeutic utility of adding a microRNA therapeutic to this emerging standard of care. In these preclinical studies, treatment with RG-012 was shown to protect kidney function better than ramipril alone ...
It isn't the seasoning, it's the inability to fight the institutional investor. It isn't people like me selling a few thousand shares that's moving this stock, it's the big guys selling millions.
This is significant on several levels. Yes the partnership itself will bear fruit but further it endorses the approach that ISIS is taking, validated by those in he know (Astrazenica) in the most potent form of support - money.
Zacks is a goofball site all the way around. They talk down any stock that rises to try to put a lid on it, maybe because they missed the run or can't understand why a stock might continue to run up. For a long time they claimed the run in Google was over, as it doubled and doubled again. Same with Tesla.
Are you referring to the refinancing deal? Hard to keep that quiet given how many people would be involved in requesting/providing quotes and structuring the deal.
If you meant the Astrazenica co-development deal, that's another story completely:
Uh, they have pretty much owned us since $25, so I'm not sure what you are laughing at. I'm more inclined to laugh at shorts on a rise from $18 to $25, not a decline from $25 to $18.
I hope you are right about the bounce back, I just don't see it happening.
You're kidding yourself. The DMD Moms got a petition to the White House itself and nothing came from it except some rhetoric from the FDA. Who knows, it could have irritated the FDA to the point where the FDA doesn't want to help them any more. I think what the Moms did was right on target but since the FDA is accountable to no one, it didn't have any effect.
Shorting the stock has no effect whatsoever on the efforts to get FDA approval, nor does it affect the kids in the slightest. I wish I had shorted at $50 and covered at $15 but I didnt. I was deluded by management to think they could actually do what they said they would do.
All shorting does is impact short term traders n the stock and they are solely out to make money, irregardless of the effect on anybody else.
It's what keeps Yahoo as the "carnival" of stock message boards. Yet for some reason we still come here.
The short interest in RGLS is very small. Some Biotechs have 30%+ short interest. RGLS has 1.35M shares out of 40M that are sold short.
Spamming all the boards.